Bim-targeted cancer therapy: a link between drug action and underlying molecular changes

Full text for this resource is not available from the Research Repository.

Akiyama, Toru, Dass, Crispin R and Choong, Peter F. M (2009) Bim-targeted cancer therapy: a link between drug action and underlying molecular changes. Molecular Cancer Therapeutics , 8 (12). pp. 3173-3180. ISSN 1535-7163


In the past few years, the pro-apoptotic molecule Bim has attracted increasing attention as a plausible target for tumor therapy. A variety of normal and pathological systems regulated by Bim, dependent on cell type, apoptotic stimulation, and chemotherapeutic agents, have been documented. Bim promotes anoikis of many tumor cells, such as lung cancer, breast cancer, osteosarcoma, and melanoma. Various chemotherapeutic agents use Bim as a mediating executioner of cell death. Hence, Bim suppression supports metastasis and chemoresistance. Imatinib, gefitinib, bortezomib, and Bim protein itself are spotlighted as current and future Bim-targeting therapeutic agents. The potential benefits of Bim-targeted therapies are selectivity of treatment for tumor cells and reduction in tumorassociated phenomena such as chemoresistance and metastasis. Thus, Bim-targeting therapies may provide more effective and unique tumor management modalities in future. This review article discusses all these issues.

Dimensions Badge

Altmetric Badge

Item type Article
DOI 10.1158/1535-7163.MCT-09-0685
Official URL
Subjects Historical > Faculty/School/Research Centre/Department > School of Biomedical and Health Sciences
Historical > FOR Classification > 1112 Oncology and Carcinogenesis
Historical > SEO Classification > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions)
Keywords ResPubID21873. bim-targeted cancer therapy, tumour therapy, cancer treatment, anoikis, tumours
Citations in Scopus 128 - View on Scopus
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login